Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

January 18, 2022
Briefly: A User's Guide for Post-Trial Motions
Eric Magnuson and Caroline Moos - Minnesota Lawyer
December 21, 2021
Is This the End of Mandatory Arbitration?
David Rochelson - Antitrust, Vol. 36, No. 1, Fall 2021
December 2021
The Evolution and Practical Application of Genetic Testing
Teresa Fariss McClain - The Robins Kaplan Justice Report
Winter 2021
Avoiding Guilt by Association
Denise Rahne - The Robins Kaplan Spotlight, Vol. 6, No. 4
Winter 2021
Can You Keep a Secret? And Should You?
Anne Lockner - The Robins Kaplan Spotlight, Vol. 6, No. 4
Back to Top